An update from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has received a Notice of Allowance from the Chinese Patent Office for a patent protecting its CD19-expressing oncolytic virus, onCARlytics, in China, Asia’s largest market. This patent, which extends protection until 2038, covers the method of composition and use of onCARlytics, a virus that targets solid tumor cells by forcing them to express the CD19 protein. The patent’s approval is a strategic move to secure Imugene’s intellectual property in a major market, supporting its ongoing clinical trials and reinforcing its position in the immuno-oncology industry.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors. The company’s platform technologies aim to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than synthetic monoclonal antibodies and other immunotherapies. Imugene’s pipeline includes an allogeneic CAR T cell therapy targeting CD19 for blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy for various cancers. Supported by international cancer experts, Imugene aims to transform cancer treatment and improve patient outcomes.
YTD Price Performance: 20.0%
Average Trading Volume: 152,307
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $175.2M
See more insights into IMU stock on TipRanks’ Stock Analysis page.